At what enterprise value was NXSTAGE MEDICAL acquired in 2017?

During the acquisition of NXSTAGE MEDICAL by FRESENIUS in 2017, the transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR.

When was NXSTAGE MEDICAL acquired by FRESENIUS?

NXSTAGE MEDICAL was acquired by FRESENIUS in 2017.

What was the revenue of NXSTAGE MEDICAL at the time of the deal?

The revenue of NXSTAGE MEDICAL at the time of the deal is estimated to be in the range of 250M - 500M EUR.

How is the data for the NXSTAGE MEDICAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NXSTAGE MEDICAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://freseniusmedicalcare.com/en-us/company/our-company/news-releases/fresenius-medical-care-to-acquire-nxstage-medical-inc/

← DATABASE

Home Database Healthcare & PharmaNXSTAGE MEDICAL

09/2017

NXSTAGE MEDICAL acquired by FRESENIUS

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment EV 1b - 4b EUR

Context

Fresenius Medical Care announced a definitive agreement to acquire all outstanding shares of NxStage Medical. The acquisition is strategically central to FMC's 2020 strategic initiative, positioning the combined entity as a global leader in home dialysis by integrating NxStage's System One platform into FMC's vertically integrated dialysis ecosystem. The transaction is expected to generate net cost synergies of approximately $80–100 million per annum before tax over three to five years, with integration costs of approximately $150 million over the first three years. FMC expects the acquisition to be accretive to net income and EPS within three years of closing.

NXSTAGE MEDICAL, which reported an EBITDA margin of in 2016, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

NxStage Medical is a US-based medical technology company founded in 1998, specialising in the development, manufacture, and marketing of innovative medical devices for home dialysis and critical care settings. The company's flagship product is the System One, a portable home haemodialysis (HHD) machine that represents the most advanced home dialysis platform available in the US market and is sold primarily to Fresenius Medical Care North America and its main competitor DaVita. NxStage also develops products for acute kidney failure treatment in critical care environments and has established a small number of dialysis clinics dedicated to developing innovative care delivery models for end-stage renal disease (ESRD) patients.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
10/2017	UI INVESTISSEMENT / BPIFRANCE	THERADIAL	FRANCE	Medical Devices
10/2017	CVC	SEBIA	FRANCE	Diagnostic Equipment
06/2017	EQT PARTNERS	OTTOBOCK	GERMANY	Implants & Prosthetics
06/2017	CHARTERHOUSE	SERB	BELGIUM	Pharma & Biotech
05/2017	PAI PARTNERS	ELITECH GROUP	FRANCE	Diagnostic Equipment
04/2017	BAIN CAPITAL / CINVEN	STADA	GERMANY	Generics / Labs
04/2017	NORDSON CORPORATION	VENTION ADVANCED TECHNOLOGIES	UNITED KINGDOM	Medical Devices
03/2017	ARDIAN	UNITHER	FRANCE	CDMO
02/2017	ECOLAB	LABORATOIRES ANIOS	FRANCE	Medical Consumables
09/2016	ARCHIMED	POLYPLUS	FRANCE	R&D Biotech

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NXSTAGE MEDICAL by FRESENIUS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: fresenius